Drug Profile

Lenalidomide - Celgene Corporation

Alternative Names: CC-5013; CDC-501; CDC-5013; ENMD-0997; IMiD-1; IMiD-3; Ladevina; Revimid™; REVLIMID

Latest Information Update: 04 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Celgene Corporation
Developer Baylor College of Medicine; BeiGene; Celgene Corporation; Dana-Farber Cancer Institute; Groupe dEtude des Lymphomes de lAdulte; H. Lee Moffitt Cancer Center and Research Institute; Helsinki University Central Hospital; Indiana University School of Medicine; IRCCS San Raffaele; Massachusetts General Hospital; National Cancer Institute (USA); Nordic MDS Study Group; Novartis; Ohio State University Comprehensive Cancer Center; Peking Union Medical College Hospital; Roche; Roswell Park Cancer Institute; Royal Marsden NHS Foundation Trust; SCRI Development Innovations; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of California, Davis; University of Florida; University of Wuerzburg; Washington University School of Medicine; Weill Cornell Medical College
Class 2 ring heterocyclic compounds; Antineoplastics; Imides; Isoindoles; Piperidones; Small molecules
Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cell proliferation inhibitors; Immunomodulators; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors; Vascular endothelial growth factors inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Multiple myeloma; Adult T-cell leukaemia-lymphoma; Myelodysplastic syndromes; Chronic lymphocytic leukaemia
New Molecular Entity Yes

Marketed Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes
Registered Adult T-cell leukaemia-lymphoma
Preregistration Non-Hodgkin's lymphoma
Phase III Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
Phase II Acute myeloid leukaemia; Bladder cancer; Histiocytosis; Hodgkin's disease; Myelofibrosis; POEMS syndrome; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
Phase I/II Non-small cell lung cancer
No development reported Cancer; Chronic myeloid leukaemia; Eye neoplasms; Glioblastoma; Peripheral T-cell lymphoma; Prostate cancer; Solid tumours
Discontinued Colorectal cancer; Heart failure; Inflammation; Liver cancer; Malignant melanoma

07 Dec 2024 Efficacy data from the phase III StaMINA trial in Multiple myeloma presented at the 66^th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
04 Oct 2024 Mayo Clinic completes a phase I/II trial in Follicular lymphoma and Diffuse large B cell lymphoma (Newly diagnosed, Combination therapy) in USA (PO) (NCT00670358)
07 May 2024 Phase-III clinical trials in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater, Late-stage disease) in China (PO) (NCT06521255)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com